Dishman Carbogen Amics Ltd
DCAL
Company Profile
Business description
Dishman Carbogen Amics Ltd is a biotechnology company that provides contract research and manufacturing services for pharmaceutical companies. It manufactures bulk drugs, specialty chemicals, and outsourced goods. Additionally, the company produces vitamins, such as vitamin D2 and vitamin D3, reagents, antiseptics and disinfectants, transfer catalysts, personal-care ingredients, pharma intermediates, and ammonium and phosphonium high-purity solid Quats. The business generates the vast majority of its revenue in India.
Contact
Iscon-Bopal Road
Dishman Corporate House
Ambli
AhmedabadGJ380 058
INDT: +91 2717420124
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2025
Employees
1,132
Stocks News & Analysis
stocks
The ASX healthcare player soaring to all-time highs
The steep market reaction comes after a recent announcement by the ACCC
stocks
Ask the analyst: How long is WiseTech's growth runway?
Roy Van Keulen answers my question on how big a growth opportunity remains for the ASX's biggest technology company.
video
Why the ASX's most overlooked world champion is no dinosaur
Brambles is the undisputed king of pallet pooling. Esther Holloway joined me to talk about its moat, growth prospects and risk of disruption.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,416.60 | 57.70 | -0.68% |
| CAC 40 | 7,541.36 | 63.58 | 0.85% |
| DAX 40 | 19,120.93 | 105.52 | 0.55% |
| Dow JONES (US) | 42,352.75 | 341.16 | 0.81% |
| FTSE 100 | 8,280.63 | 1.89 | -0.02% |
| HKSE | 22,736.87 | 623.36 | 2.82% |
| NASDAQ | 18,137.85 | 219.37 | 1.22% |
| Nikkei 225 | 38,635.62 | 83.56 | 0.22% |
| NZX 50 Index | 12,619.94 | 47.28 | 0.38% |
| S&P 500 | 5,751.07 | 51.13 | 0.90% |
| S&P/ASX 200 | 8,150.00 | 55.20 | -0.67% |
| SSE Composite Index | 3,336.50 | 248.97 | 8.06% |